Search results for " Colon cancer"

showing 10 items of 61 documents

In vivo efficacy of verteporfin loaded gold nanorods for combined photothermal/photodynamic colon cancer therapy.

2022

The high incidence of cancer recurrences and the frequent occurrence of multidrug resistance often stem from a poorly selective and inefficient antineoplastic therapy, responsible for the onset of undesired side effects as well. A combination of minimal-invasive approaches could thus be a useful strategy to surmount these shortcomings, achieving a safe and solid cancer therapy. Herein, a multi-therapeutic nanotool was designed by merging the photothermal properties of gold nanorods (AuNRs) with the photodynamic activity of the photosensitizer ver-teporfin. AuNRs were coated with the natural materials lipoic acid and gellan gum (AuNRs_LA,GG) and subse-quently loaded with verteporfin (AuNRs_L…

NanotubesHuman colon cancerPharmaceutical ScienceVerteporfinHyperthermia InducedPhototherapyGold nanorodsPhotothermal therapyGellan gumPhotodynamic therapyMiceCell Line TumorColonic NeoplasmsAnimalsHumansGoldInternational journal of pharmaceutics
researchProduct

Saponins from the Roots of Nylandtia spinosa

2007

From the roots of Nylandtia spinosa, four new triterpene saponins, 3- O-beta- d-glucopyranosylpresenegenin 28- O-beta- d-galactopyranosyl-(1-->4)-[alpha- l-arabinopyranosyl-(1-->3)]-beta- d-xylopyranosyl-(1-->4)-[beta- d-apiofuranosyl-(1-->3)]-alpha- l-rhamnopyranosyl-(1-->2)-beta- d-fucopyranosyl ester ( 1), 3- O-beta- d-glucopyranosylpresenegenin 28- O-beta- d-galactopyranosyl-(1-->4)-[alpha- l-arabinopyranosyl-(1-->3)]-beta- d-xylopyranosyl-(1-->4)-alpha- l-rhamnopyranosyl-(1-->2)-beta- d-fucopyranosyl ester ( 2), 3- O-beta- d-glucopyranosylpresenegenin 28- O-beta- d-apiofuranosyl-(1-->4)-[beta- d-galactopyranosyl-(1-->2)]-beta- d-xylopyranosyl-(1-->4)-alpha- l-rhamnopyranosyl-(1-->2)-be…

Nylandtia spinosaCoumaric AcidsSpermidineStereochemistrySaponinPharmaceutical SciencePharmacognosyPlant RootsAnalytical ChemistryInhibitory Concentration 50TriterpeneDrug DiscoveryHumansNuclear Magnetic Resonance BiomolecularPharmacologychemistry.chemical_classificationPlants MedicinalMolecular StructureChemistryOrganic ChemistryGlycosideTenuifolinSaponinsTriterpenesTerpenoidPolygalaceaeHuman colon cancerComplementary and alternative medicineMolecular MedicineDrug Screening Assays AntitumorJournal of Natural Products
researchProduct

Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer

2020

BACKGROUND: Colon cancer (CC) is a heterogeneous disease. Novel prognostic factors beyond pathological staging are required to accurately identify patients at higher risk of relapse. Integrating these new biological factors, such as plasma circulating tumour DNA (ctDNA), CDX2 staining, inflammation-associated cytokines and transcriptomic consensus molecular subtypes (CMS) classification, into a multimodal approach may improve our accuracy in determining risk of recurrence.; METHODS: One hundred and fifty patients consecutively diagnosed with localised CC were prospectively enrolled in our study. ctDNA was tracked to detect minimal residual disease by droplet digital PCR. CDX2 expression was…

OncologyCancer Researchmedicine.medical_specialtyColorectal cancerPathological stagingConsensus molecular subtypesPerineural invasionlcsh:RC254-282Circulating Tumor DNAInternal medicinemedicineBiomarkers TumorHumansDigital polymerase chain reactionCDX2 Transcription Factor1506plasma circulating-tumor DNAStage (cooking)Original Researchbusiness.industryInterleukin-6Plasma circulating-tumor DNA.Multimodal therapymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisMinimal residual diseaseColon cancerOncologyColonic NeoplasmsCDX2 homeoprotein; colon cancer; consensus molecular subtypes; interleukin-6; plasma circulating-tumor DNANeoplasm Recurrence LocalbusinessCDX2 homeoproteinImmunostaining
researchProduct

Prognostic Impact of pT Stage and Peritoneal Invasion in Locally Advanced Colon Cancer

2019

BACKGROUND: TNM stage has been identified as an independent variable for local recurrence and survival after colon cancer resection. It is still unclear whether peritoneal invasion (pT4a) is a risk factor for adverse oncologic outcome or whether these patients have better results compared with contiguous organs infiltration (pT4b), independent from nodal status (pN). OBJECTIVE: The purpose of this study was to analyze whether peritoneal invasion is an independent risk factor for worse oncologic outcome after curative colon cancer resection. DESIGN: This was a retrospective analysis with multivariate regression of a prospective database, according to Strengthening the Reporting of Observatio…

OncologyMalemedicine.medical_specialtySurvivalColorectal cancermedicine.medical_treatmentLocally advancedT stageLocally advanced colon cancer03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineColon cancer resectionHumansNeoplasm InvasivenessRisk factorStage (cooking)Survival rateColectomyPeritoneal NeoplasmsColectomyAgedNeoplasm StagingRetrospective StudiesCarcinomatosisTumor-node-metastasisbusiness.industryGastroenterologyRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseasePrognosisColon cancerSurvival RateTreatment Outcome030220 oncology & carcinogenesisColonic Neoplasms030211 gastroenterology & hepatologyFemaleNeoplasm Recurrence Localbusiness
researchProduct

Efficacy of zoledronic acid in patients with colorectal cancer metastatic to bone

2011

Oncologymedicine.medical_specialtyHistologyPhysiologybusiness.industryColorectal cancerEndocrinology Diabetes and MetabolismBone metastasismedicine.diseaseZoledronic acidInternal medicinemedicineIn patientbusinessmedicine.drugMetastatic colon cancerBone
researchProduct

Novel P53 mutations detected by FAMA in colorectal cancers

2006

Background The aim of the study was to identify p53 gene mutations by FAMA (fluorescence-assisted mismatch analysis) in colorectal cancers. Patients and methods Analytical scanning of the p53 gene (exons 5–9) was performed in colon cancer samples from 44 consecutive patients by FAMA. FAMA is a semiautomatic scanning approach based on the chemical cleavage of the mismatch in fluorescently labeled heteroduplex DNA, obtained from the combination of a normal and a mutated allele. FAMA has already shown optimal levels of diagnostic accuracy and sensitivity in detecting gene mutations (nucleotide substitutions, insertions/deletions) both at the germline and somatic level. The peculiar feature of …

Oncologymedicine.medical_specialtyMutantDNA Mutational AnalysisMutation MissenseGene mutationmedicine.disease_causeExonInternal medicinemedicineMissense mutationHumansKey words: colon cancer p53 mutations FAMAAlleleGeneMutationbusiness.industryHematologyDNA NeoplasmExonsGenes p53Molecular biologyOncologybusinessColorectal NeoplasmsHeteroduplex
researchProduct

27. Differences in adjuvant chemotherapy administration for stage II colon cancer patients – a EURECCA international comparison

2014

Oncologymedicine.medical_specialtyOncologybusiness.industryAdjuvant chemotherapyInternal medicinemedicineSurgeryGeneral MedicinebusinessAdministration (government)Stage ii colon cancerEuropean Journal of Surgical Oncology (EJSO)
researchProduct

ADVANCED ENDOSCOPIC IMAGING FOR SURVEILLANCE FOR DYSPLASIA AND COLORECTAL CANCER IN INFLAMMATORY BOWEL DISEASE: COULD THE PATHOLOGIST BE FURTHER HELP…

2014

Patients with inflammatory bowel disease (IBD) have an increased risk of developing intestinal cancer. The magnitude of that increased risk as well as how best to mitigate it remain a topic of ongoing investigation in the field. It is important to quantify the risk of colorectal cancer in association with IBD. The reported risk varies widely between studies. This is partly due to the different methodologies used in the studies. Because of the limitations of surveillance strategies based on the detection of dysplasia, advanced endoscopic imaging and techniques involving the detection of alterations in mucosal antigens and genetic abnormalities are being investigated. Development of new bioma…

Pathologymedicine.medical_specialtyColorectal cancerReview ArticleComorbidityInflammatory bowel diseaseEndoscopy GastrointestinalADVANCED ENDOSCOPIC IMAGING DYSPLASSIA COLON CANCER IBDEndoscopic imagingRisk Factorsinflammatory bowel diseasemedicineHumanslcsh:RC799-869Intestinal Cancerulcerative colitisPatient Care TeamCrohn's diseaseSettore MED/12 - GastroenterologiaMicroscopy Confocalbusiness.industryCrohn′s diseaseGastroenterologyInflammatory Bowel Diseasesmedicine.diseaseUlcerative colitisColorectal cancerdigestive system diseasesCrohn's diseaseSettore MED/18 - Chirurgia GeneraleDysplasiaPopulation SurveillancesurveillanceBiomarker (medicine)lcsh:Diseases of the digestive system. GastroenterologyColorectal Neoplasmsbusiness
researchProduct

Intramedullary spinal cord tumor presenting as the initial manifestation of metastatic colon cancer: case report and review of the literature

2007

Study design: Case reports and review of the literature. Objective: Intramedullary spinal cord metastases (ISCMs) are rare type of central nervous system (CNS) involvement of systemic malignant tumors. Since the advent of new neuroradiological techniques, their detection have become increasingly diagnosed in recent years and, although somewhat controversial, surgical treatment has been considered a valid option. Setting: Neurosurgical Clinic, Department of Clinic Neuroscience, University of Palermo, Italy. Method: The authors describe the case of a 61-year-old woman who was admitted presenting withprogres sive tetraplegia. Investigations revealed an intramedullary spinal cord lesion at the …

Pathologymedicine.medical_specialtyIntramedullary tumorColorectal cancerIntramedullary spinal cordMetastasiQuadriplegiaMetastasisCentral nervous system diseaseFatal OutcomemedicinemetastasisHumansSpinal Cord NeoplasmsMetastatic colon cancerNeurologic Examinationadenocarcinomabusiness.industryCarcinomaLaminectomyCancerGeneral MedicineMiddle Agedmedicine.diseaseMagnetic Resonance ImagingSpinal cord tumorNeurologyColonic NeoplasmsAdenocarcinomaFemaleNeurology (clinical)businessSpinal Cord
researchProduct

What is the best surgical option for the resection of transverse colon cancer?

2019

Transverse colon is an infrequent localization of colon cancer and it is burdened by a poor prognosis. The principle of oncological radicality includes primary tumor resection with adequate lymphadenectomy. To date, there is still no consensus on which type of surgical resection perform in case of transverse colon cancer (TCC). Lymphatic drainage and vascularization of this section of the colon is highly variable presenting with different anatomical variants. Moreover, mobilization of the transverse colon can be particularly challenging in comparison to other colon tracts. Despite a lack of standardized definitions, three main surgical options are proposed: segmental colectomy of the transv…

Poor prognosismedicine.medical_specialtybusiness.industryColorectal cancermedicine.medical_treatmentTransverse colon cancer (TCC)Transverse colonmedicine.diseasePrimary tumorextended colectomy (EC)Resectiontransverse colectomy (TC)Transverse ColectomyMedicineSurgeryLymphadenectomyRadiologybusinessTransverse colon cancersubtotal colectomy (STC)
researchProduct